Tilray (TLRY): Five-Year Losses Increase 31.4% Annually, Profit Remains Elusive Heading Into Earnings

Simply Wall St.

Oct 10

Tilray Brands (TLRY) remains unprofitable, recording losses that have increased at an average annual rate of 31.4% over the past five years. The company is not expected to turn a profit within the ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2574811855"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2574811855\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2574811855?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice1-main-header/1585186685410","is_english":true,"pubTime":"2025-10-10 06:22","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2574811855","market":"nz","top_or_hot":-1,"title":"Tilray (TLRY): Five-Year Losses Increase 31.4% Annually, Profit Remains Elusive Heading Into Earnings","media":"Simply Wall St.","content":"<div>\n<p>Tilray Brands (TLRY) remains unprofitable, recording losses that have increased at an average annual rate of 31.4% over the past five years. The company is not expected to turn a profit within the ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-tlry/tilray-brands/news/tilray-tlry-five-year-losses-increase-314-annually-profit-re\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Tilray (TLRY): Five-Year Losses Increase 31.4% Annually, Profit Remains Elusive Heading Into Earnings</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTilray (TLRY): Five-Year Losses Increase 31.4% Annually, Profit Remains Elusive Heading Into Earnings\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-10-10 06:22 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-tlry/tilray-brands/news/tilray-tlry-five-year-losses-increase-314-annually-profit-re><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Tilray Brands (TLRY) remains unprofitable, recording losses that have increased at an average annual rate of 31.4% over the past five years. The company is not expected to turn a profit within the ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-tlry/tilray-brands/news/tilray-tlry-five-year-losses-increase-314-annually-profit-re\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"TLRY","symbol_name":"Tilray Inc.","start_time":0,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-tlry/tilray-brands/news/tilray-tlry-five-year-losses-increase-314-annually-profit-re","article_id":"2574811855","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice1-main-header/1585186685410"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-tlry/tilray-brands/news/tilray-tlry-five-year-losses-increase-314-annually-profit-re","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2574811855","pubTimestamp":1760048560,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"Tilray Brands (TLRY) remains unprofitable, recording losses that have increased at an average annual rate of 31.4% over the past five years. The company is not expected to turn a profit within the next three years. Revenue growth is projected at just 4.5% per year, which is well behind the US market average of 9.9% per year. With these trends, investors are left weighing potential upside against ongoing risks and limited signs of near-term profit momentum.\nSee our full analysis for Tilray...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"TLRY":"Tilray Inc."},"translate_title":"Tilray(TLRY)：五年亏损每年增加31.4%，利润仍难以实现盈利","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"TLRY":1.5},"content_text":"Tilray Brands (TLRY) remains unprofitable, recording losses that have increased at an average annual rate of 31.4% over the past five years. The company is not expected to turn a profit within the next three years. Revenue growth is projected at just 4.5% per year, which is well behind the US market average of 9.9% per year. With these trends, investors are left weighing potential upside against ongoing risks and limited signs of near-term profit momentum. See our full analysis for Tilray Brands. The next section will compare these headline numbers with the most talked-about market narratives, highlighting where investor expectations align or clash with the data. See what the community is saying about Tilray Brands NasdaqGS:TLRY Earnings & Revenue History as at Oct 2025 AdvertisementEuropean Revenue Jumps 112% Year-on-Year  Tilray’s international cannabis business grew European cannabis revenue by 112% year-over-year (excluding Australia), driven by regulatory tailwinds and greater medical adoption. This signals significant top-line potential beyond the slow US growth rate already highlighted.  Analysts' consensus view notes that expansion in Europe and diversification into new categories support long-term revenue and margin growth. However,\n     persistent regulatory hurdles and industry headwinds continue to constrain profitability and expose Tilray to market and dilution risk future growth depends on sustaining international momentum while navigating ongoing cannabis sector volatility   To see what is influencing market expectations and how the community weighs these strategic moves, check out the full take on Tilray's evolving global story. 📊 Read the full Tilray Brands Consensus Narrative.  Price-to-Sales Looks Cheap, But the Stock Trades Above DCF Fair Value  The current Price-to-Sales ratio is 2.8x, which is well below the US Pharmaceuticals industry average of 4.7x and the peer average of 10x. The $2.1 share price remains above the DCF fair value of $1.18.  According to the consensus narrative, analysts weigh this discount-to-peer valuation against Tilray’s lack of near-term profitability and slowing revenue growth:\n     the low Price-to-Sales signals relative value compared to industry peers but limited profit momentum and the premium to DCF fair value raise questions about upside based solely on fundamentals    Share Dilution and Net Losses Raise Capital Concerns  Tilray is expected to increase its shares outstanding by 7% annually for the next three years, and reported a net loss of $2.2 billion last year, underscoring persistently negative free cash flow and challenges achieving sustainable earnings.  Analysts' consensus view highlights that persistent dilution and ongoing net losses heighten solvency and dilution risk for investors:\n     even as Tilray maintains a solid balance sheet and executes cost optimization, lack of profit acceleration and stable share price remain central risks ongoing access to capital comes at the cost of dilution and uncertain path to industry-average margins     Next Steps To see how these results tie into long-term growth, risks, and valuation, check out the full range of community narratives for Tilray Brands on Simply Wall St. Add the company to your watchlist or portfolio so you'll be alerted when the story evolves. Have your own take on the figures? It only takes a few minutes to add your perspective. Shape the story yourself and make it count. Do it your way A great starting point for your Tilray Brands research is our analysis highlighting 3 important warning signs that could impact your investment decision. See What Else Is Out There Tilray's persistent net losses, slow revenue growth, and ongoing share dilution raise concerns about its financial health and ability to achieve sustainable profitability. If you want steadier finances and less dilution risk, check out solid balance sheet and fundamentals stocks screener to discover companies built on stronger balance sheets and solid financial foundations.  This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.Valuation is complex, but we're here to simplify it.Discover if Tilray Brands might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}